Literature DB >> 3823673

Sample size requirements and the cost of a randomized clinical trial with repeated measurements.

D A Bloch.   

Abstract

This paper discusses the advantage of using repeated outcome measurements on subjects in a clinical trial. We choose the number of subjects and the number of repeated outcome measurements to minimize a given cost function so that the clinical trial has power (1-beta) for specified significance level alpha. An example illustrates the results and emphasizes the importance of study design and of critical evaluation of how one measures the study endpoint.

Mesh:

Year:  1986        PMID: 3823673     DOI: 10.1002/sim.4780050613

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Authors:  Camille Vong; Martin Bergstrand; Joakim Nyberg; Mats O Karlsson
Journal:  AAPS J       Date:  2012-02-17       Impact factor: 4.009

2.  Sample size computations for PK/PD population models.

Authors:  Dongwoo Kang; Janice B Schwartz; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

3.  Sample size determination for repeated measurements in bioequivalence test.

Authors:  K J Lui
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

4.  Power Analysis for Models of Change in Cluster Randomized Designs.

Authors:  Wei Li; Spyros Konstantopoulos
Journal:  Educ Psychol Meas       Date:  2016-04-07       Impact factor: 2.821

5.  Adding Subjects or Adding Measurements in Repeated Measurement Studies Under Financial Constraints.

Authors:  Song Zhang; Chul Ahn
Journal:  Stat Biopharm Res       Date:  2011-02-01       Impact factor: 1.452

6.  Power and sample size calculations for longitudinal studies estimating a main effect of a time-varying exposure.

Authors:  Xavier Basagaña; Donna Spiegelman
Journal:  Stat Methods Med Res       Date:  2010-06-14       Impact factor: 3.021

7.  Optimal design of studies of influenza transmission in households. I: case-ascertained studies.

Authors:  B Klick; G M Leung; B J Cowling
Journal:  Epidemiol Infect       Date:  2011-03-22       Impact factor: 2.451

8.  Optimal combination of number of participants and number of repeated measurements in longitudinal studies with time-varying exposure.

Authors:  Jose Barrera-Gómez; Donna Spiegelman; Xavier Basagaña
Journal:  Stat Med       Date:  2013-06-05       Impact factor: 2.373

9.  Prevention of epidural morphine-induced respiratory depression with intravenous nalbuphine infusion in post-thoracotomy patients.

Authors:  A D Baxter; B Samson; J Penning; R Doran; L M Dube
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

10.  Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification?

Authors:  J T Sharp; F Wolfe; M Corbett; H Isomaki; D M Mitchell; D E Furst; J Sibley; M Shipley
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.